Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-label Multi-center Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of Apremilast in Subjects With Recalcitrant Plaque-type Psoriasis

NCT00521339 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT00521339
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00521339 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-label Multi-center Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of Apremilast in Subjects With Recalcitrant Plaque-type Psoriasis
Lead sponsor
Amgen
Phase
Phase 2
Overall status
Completed
Start date
August 1, 2007
Completion date
May 1, 2009
Enrollment
31 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

plaque-type psoriasis, psoriasis-type psoriasis